New anti-VEGF agent shows promising durability

• Posted on: Jan 21 2019
• By: Saratoga Opthalmology
• Leave a response

In this phase 3 trial, researchers evaluated the efficacy and safety of intravitreal conbercept, a new anti–VEGF drug for wet AMD.
Source: AAO

Posted in: Uncategorized